EcoDrugPlus

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2-Like

Ensembl ID : ENSLBEG00000023458
Gene Symbol: LOC110000794
3 Cross references
207 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSLBEG00000016210
Gene Symbol: PDPK1
3 Cross references
221 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase B

Ensembl ID : ENSLBEG00000022884
Gene Symbol: HPDB
1 Cross references
204 Possible Orthologues:

40s Ribosomal Protein S19

Ensembl ID : ENSLBEG00000001323
Gene Symbol: LOC109996314
3 Cross references
308 Possible Orthologues:

40s Ribosomal Protein S21

Ensembl ID : ENSLBEG00000006007
Gene Symbol: LOC109996373
3 Cross references
257 Possible Orthologues:

40s Ribosomal Protein S4-Like

Ensembl ID : ENSLBEG00000016895
Gene Symbol: LOC109977295
3 Cross references
493 Possible Orthologues:

40s Ribosomal Protein S5-Like

Ensembl ID : ENSLBEG00000019288
Gene Symbol: LOC109978587
3 Cross references
263 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSLBEG00000002111
Gene Symbol: LOC110000384
4 Cross references
515 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSLBEG00000013717
Gene Symbol: NT5E
3 Cross references
214 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSLBEG00000022439
Gene Symbol: NT5E
4 Cross references
214 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta

Ensembl ID : ENSLBEG00000017184
Gene Symbol: LOC109985696
3 Cross references
137 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSLBEG00000014485
Gene Symbol: HTR1B
1 Cross references
183 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).